Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMEN-803: N-803 Maintenance Post CAR T-cell Therapy in B-cell NHL
NCT07049432Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in B-cell non-Hodgkin lymphoma, sponsored by University of Utah. Primary endpoints: Maximum Tolerated Dose at 4 years and Recommended Phase 2 Dose at 4 years. Planned start Feb 2026; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07049432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049432.